The House Energy and Commerce Oversight and Investigations Subcommittee hearing on reforming the 340B outpatient drug discount program showcased the ongoing lack of broad bipartisan agreement on legislation addressing the issue.
Key Takeaways
-
Republicans and Democrats on the committee are not in alignment on how Congress should address possible reforms to the 340B drug discount program.
Over the past several years, Congress has taken incremental steps toward enhancing oversight of the program and clarifying its scope....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?